NASDAQ: KTTAPasithea Therapeutics Corp Stock
$7.15-0.31 (-4.16%)
Updated Apr 15, 2024
KTTA Price
$7.15
Fair Value Price
$13.25
Market Cap
$7.45M
52 Week Low
$5.25
52 Week High
$17.40
P/E
-0.55x
P/B
0.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.96M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
-$13M
Beta
0.66
Next Earnings
May 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A
KTTA Overview
Pasithea Therapeutics Corporation is a biotech company developing treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics was incorporated in 2020 and is headquartered in Miami Beach, FL.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KTTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KTTA ($7.15) is undervalued by 46.03% relative to our estimate of its Fair Value price of $13.25 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KTTA ($7.15) is significantly undervalued by 46.03% relative to our estimate of its Fair Value price of $13.25 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KTTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KTTA due diligence checks available for Premium users.
Be the first to know about important KTTA news, forecast changes, insider trades & much more!
KTTA News
Valuation
KTTA fair value
Fair Value of KTTA stock based on Discounted Cash Flow (DCF)
Price
$7.15
Fair Value
$13.25
Undervalued by
46.03%
KTTA ($7.15) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KTTA ($7.15) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KTTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KTTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.55x
Industry
14.94x
Market
41.94x
KTTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.32x
Industry
5.88x
KTTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KTTA's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.0M
Profit Margin
0%
KTTA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$26.1M
Liabilities
$2.7M
Debt to equity
0.12
KTTA's short-term assets ($16.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KTTA's short-term assets ($16.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KTTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.3M
Investing
$54.5k
Financing
$0.0
KTTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KTTA vs Biotech Stocks
Pasithea Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.